Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

CALGARY, March 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2008.

"In 2008, we selected our first pivotal program for REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "The selection of head and neck cancers was supported by interim results reported in our US and UK clinical studies, and the successful development of a manufacturing process capable of supplying REOLYSIN for large clinical studies."

    Selected Highlights:

    Clinical Trial Results
    ----------------------

    -   Announced positive interim results from our Phase I/II UK combination
        REOLYSIN and carboplatin/paclitaxel trial. Of 14 patients evaluable
        for response, four had partial responses and five patients had stable
        disease. Of note, all partial responses and 4/5 stable diseases were
        in head and neck disease;

    -   Announced positive interim results from our UK combination REOLYSIN
        and docetaxel trial. Of the 11 patients evaluable for response, five
        had partial or minor responses, and six patients had stable disease;
        and

    -   Exceeded the primary statistical endpoint in our US multicentre,
        Phase 2 clinical trial to evaluate the intravenous administration of
        REOLYSIN in patients with various sarcomas that had metastasized to
        the lung. We reported that of 33 patients evaluable for response,
        five had stable disease for more than six months, and an additional
        10 patients had stable disease ranging from 3-6 cycles
        (cycle = 28 days).

    Clinical Trial Progress
    -----------------------

    -   Selection of first pivotal program using REOLYSIN in combination with
        paclitaxe
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... Research Triangle Park, NC (PRWEB) January 14, 2014 ... diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel ... on their first round of financing netting a total of ... first outside equity capital in the company. This group of ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... 29 Reportlinker.com announces that a ... in its catalogue. , ... Broadening Market , ... diagnostic applications in the areas of ...
... Zealand, Oct. 29 ZyGEM Corp. Ltd., a provider ... life sciences applications, today announced it has entered into ... DNA extraction products to the Japanese market. This ... recent major distribution agreements for ZyGEM,s DNA extraction kits ...
... 29 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management ... Thursday, October 29 at 10:00 a.m. Pacific Time. , The conference is being ... presentation will be webcast live with slides and available for replay afterwards. The ... ...
Cached Biology Technology:Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 2Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 3Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 4Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 5Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening Market 6ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 2ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 3ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 4
(Date:4/18/2014)... researchers have published soil organic carbon sequestration rates. ... organic carbon can be sequestered by simply switching from ... there is a growing body of research with evidence ... cover crops, small grains, and forages may not be ... , "Some studies have shown that both moldboard and ...
(Date:4/17/2014)... April 17 In the most densely forested and ... reflect two centuries of human needs, values and practices. ... clearing forests for agriculture and development, have set the ... U.S. Forest Service study reports. , The report ... and management needs in the Northern United States ...
(Date:4/17/2014)... West Orange, NJ. April 16, 2014. Kessler Foundation ... for $1.8 million from the Department of Defense ... PhD, is principal investigator for the randomized, double-blinded, ... to improve bone and muscle strength after spinal ... Human Performance & Engineering Research at Kessler Foundation. ...
Breaking Biology News(10 mins):Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... more about a tumor,s underlying biology, personalized medicine ... This year, the American Association for ... in Cancer Therapeutic Development: Challenges and Horizons conference ... Colo. This meeting regularly draws representatives from academia ...
... Pancreatic cancers use the sugar fructose, very common in ... drives cell division, helping the cancer to grow more quickly, ... has found. Although it,s widely known that cancers use ... the first time a link has been shown between fructose ...
... August 3rd, as part of the Ecological Society ... of scientists will discuss the environmental impacts of ... some of the most diverse habitats on the ... altered by mountaintop removal and valley fill mining. ...
Cached Biology News:Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 2Pancreatic cancers use fructose, common in the Western diet, to fuel their growth 3Ecologists to discuss impacts of mountaintop mining at special ESA symposium 2Ecologists to discuss impacts of mountaintop mining at special ESA symposium 3
... Probes EnzChek Pyrophosphate Detection Kit,provides a ... measuring the inorganic pyrophosphate (PPi ) ... such as DNA and,RNA polymerizations, cyclic ... and the enzymatic activation of fatty ...
... is an intracellular marker normally present at ... subpopulation of bone marrow prelymphocytes. Elevated levels ... TdT cells are found to be associated ... of TdT thus provides a useful adjunct ...
... NOT FREEZE. Nuclear matrix proteins (NMPs) make up ... are associated with such functions as DNA replication, ... nuclear matrix has been shown to be highly ... known that cell death releases soluble nuclear matrix ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
Biology Products: